HALO | Ticker Profile - Titan Protect

HALO

Halozyme Therapeutics, Inc.

Healthcare · Biotechnology · NMS

$71.53

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$8.1B

Total market value of the company

Trailing P/E

24.09

Premium valuation

Forward P/E

6.94

Based on estimated future earnings — lower means cheaper

Rev Growth

+42.2%

Year-over-year revenue change

Profit Margin

23.1%

How much profit the company keeps from each dollar of revenue

ROE

99.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$89.00

+24% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 10 analysts covering this stock

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

https://halozyme.com

Country: United States Employees: 423 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.777

Good returns relative to risk taken

Kelly Fraction

0.0758

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.780

Acceptable balance between returns and drawdown risk

Annual Return

26.5%

Historical annualised return based on price data

Max Drawdown

-33.9%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.88

Less volatile than the market — more defensive

52W High

$82.22

13% below the year high

52W Low

$51.06

40% above the year low

Avg Volume

1,610,378

Average daily shares traded — higher means easier to buy and sell

Short Ratio

7.9

Days it would take all short sellers to cover — higher means more crowded

Short % Float

14.6%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$2.85

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

991.21

Heavy leverage — higher financial risk if revenues decline

Current Ratio

2.76

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

2.14

Like current ratio but excludes inventory — stricter test

Gross Margin

76.7%

Revenue left after cost of goods — higher means pricing power

Operating Margin

49.0%

Profit from core operations before interest and tax

Free Cash Flow

$228M

Positive — the business generates more cash than it spends

Revenue (TTM)

$1.5B

Total revenue over the last 12 months

Net Income

$349M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$96.00

Target Median

$89.00

Target Low

$57.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go